Afghanistan vs Nigeria: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Afghanistan
63.0%
in 2025
Nigeria
62.0%
in 2025
Afghanistan rank
142nd
Nigeria rank
144th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Afghanistan
- Nigeria
How they compare
Afghanistan currently reports 63.0% against 62.0% in Nigeria, a difference of 1.0%.
The two have swapped places 5 times across 18 shared years of data; in 2008 it was Nigeria ahead.
Afghanistan ranks 142nd and Nigeria ranks 144th of 194 countries.
Afghanistan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Afghanistan | Nigeria | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 36.3% | 26.1% | 10.2% | Afghanistan |
| 2020s | 59.2% | 58.5% | 0.7% | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Afghanistan or Nigeria?
- Afghanistan, at 63.0% against 62.0% in Nigeria as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Afghanistan and Nigeria?
- 1.0%, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Nigeria?
- 18 years are reported by both, from 2008 to 2025.
- How do Afghanistan and Nigeria rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Afghanistan ranks 142nd and Nigeria ranks 144th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.